化合物丹申开通过网络药理学和转录学识别了它对抗动脉样硬化症的机制
Yueyue Song1,2, Wenjie Zhao1, Lei Zhang3,4
1Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250300, China.
Naunyn-Schmiedeberg's archives of pharmacology
|October 29, 2025
概括
传统中医药中的化合物丹申 (CPDD) 通过调节PI3K/AKT通路,有效治疗动脉样硬化. 其活性成分Rg1,R1和PCAD (RRP) 减少内皮细胞的炎症和斑块形成.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 传统中国医药 传统中国医药
背景情况:
- 动脉样硬化是一种普遍的心血管疾病.
- 复合丹申 (CPDD) 是一种用于治疗动脉样硬化的疾病的传统中医药 (TCM).
- 在治疗动脉样硬化时,CPDD的确切机制尚未完全理解.
研究的目的:
- 阐明CPDD在治疗动脉样硬化的药理机制.
- 在CPDD中识别活性化学成分及其目标.
- 研究特定活性成分组合 (RRP) 对动脉样硬化内皮炎的治疗作用.
主要方法:
- 四极轨道 LC-MS 用于化学成分识别.
- 转录学,网络药理学和WGCNA用于目标识别.
- 在体内研究中,使用ApoE-/-小鼠进行了油红色O,HE,Masson和红色染色.
- qRT-PCR和西布洛特用于基因和蛋白质表达分析.
主要成果:
- 在CPDD中发现了23种化学成分;确定了9种活性成分和531种潜在目标.
- 发现了活性成分组合Rg1-R1-PCAD (RRP).
- 在ApoE-/-小鼠中,RRP减少了脂质沉积,斑块区域,并改善了内皮功能.
- RRP上调调节了PIK3R1,Akt和eNOS的表达,同时降低了HSP90AA1和HSP90B1.1.
结论:
- RRP是CPDD的活性成分组合,有效地治疗动脉样硬化内皮炎症.
- 该机制涉及调节PI3K/AKT信号通路.
- 通过促进PIK3R1,Akt和eNOS的表达和抑制HSP90AA1和HSP90B1.1,CPDD的治疗效果得到了调解.
相关概念视频
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Combined Effects of Drugs: Antagonism
11.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
Antianginal Drugs: Nitrates and β-Blockers
1.4K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Antihypertensive Drugs: Action of β1 Blockers
1.9K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K

